Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Abstract Background CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) are approved for the treatment of ER+ advanced breast cancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. We previously reported a novel therapeutic agent, ERX-11, that binds to the...

Full description

Bibliographic Details
Main Authors: Suryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, Tae-Kyung Lee, Mengxing Li, Collin Gilbreath, Xihui Liu, Yiliao Luo, Uday P. Pratap, Mei Zhou, Eliot B. Blatt, Kara Kassees, Carlos Arteaga, Prasanna Alluri, Manjeet Rao, Susan T. Weintraub, Rajeshwar Rao Tekmal, Jung-Mo Ahn, Ganesh V. Raj, Ratna K. Vadlamudi
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Breast Cancer Research
Subjects:
Estrogen receptor (ER)
ER coregulators
Breast cancer
ER coregulator modulator
Therapy-resistant breast cancer
CDK4/6 inhibitor
Online Access:https://doi.org/10.1186/s13058-019-1227-8

Internet

https://doi.org/10.1186/s13058-019-1227-8

Similar Items